Do you have type 1 diabetes and kidney disease?

Nox 1 and 4 inhibition in type 1 diabetic kidney disease

Diabetic kidney disease is an important health challenge.  There is a great need to develop new treatment strategies because, even with current treatments, there may be progressive decrease in kidney function.  This could lead to kidney failure needing dialysis or kidney transplantation. In one form of diabetic kidney disease, there is leakage of abnormal amounts of protein into the urine (called “albuminuria”). The study drug is aimed at lowering urinary albumin leak and to slow down the decrease of kidney function associated with diabetic kidney disease. In summary we are testing whether a new tablet can help to treat diabetic kidney disease. 

Participants will randomly be allocated to receive either the new tablet or a placebo. This is a double-blind study which means that neither you nor your study doctor will know which treatment you are receiving. The project is designed this way to ensure that researchers interpret the results in a fair and appropriate way and avoids study doctors or participants jumping to conclusions.

Anticipated date enrolment will close: 31 December 2021

Who can take part

People with:

  • Type 1 diabetes
  • 18 to 70 years old
  • Albumin (protein) in the urine
  • HbA1c is <10%

  • There are requirements that must be met before you are allowed to take part in this study. Your study doctor will discuss these with you and will tell you if you qualify for the study after the results of the required tests and examinations are reviewed.

What is involved for you

  • The study lasts for 56 weeks and will involve 10 study visits
  • Blood and urine samples
  • Weight + Height
  • Blood Pressure
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
Marika Bjorasen
(03) 9342 7344
Diabetes Research Centre